Emergex
  • About Us
      • Team
      • Board of Directors
      • Special Advisors
      • Partners
  • Technology
      • Advantages of Emergex’s Vaccines
  • Pipeline
  • Media Centre
    • In the News
    • Press Releases
  • Careers
  • Contact Us
  • Menu Menu
You are here: Home1 / About Us

Our Vision

To improve global human health by providing long-term immunity for some of the world’s most pressing diseases.

Understand our approach in under 4 minutes

Emergex Vaccines is a clinical-stage biotechnology company headquartered near Oxford, UK, with R&D facilities in Milton Park and a USA corporation in Doylestown, Pennsylvania. Emergex Vaccines is focussed on developing a range of 100% synthetic CD8+ T cell Adaptive Vaccines that harness the body’s natural cellular immune response to destroy pathogen-infected cells and to provide immune protection for some of the world’s most impactful diseases.

Our Technology Our Advantages

Emergex’s T cell Adaptive Vaccines candidates combine two proprietary technologies

  • To offer broad, cross-reactive protection against viral mutations and viruses of the same family (one vaccine, multiple pathogen protection)
  • To extend duration of immune protection, potentially for decades
  • To enable transport and storage for extended periods of time at room temperature
  • To be delivered via micro-needles into the skin, avoiding conventional needle administration
  • To be suited for rapid ‘plug and play’ vaccine development and scale-up with passivated gold quantum cluster delivery platform.
  • Activation of T-cell by activated dendritic cell.

  • Infected cell death by T cell.

  • Dendritic cell activation.

PreviousNext
123

© EMERGEX VACCINES

Website maintained by Digital Trading

  • Contact Us
LinkedIn
Scroll to top